A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis

Ortopedia Traumatologia Rehabilitacja

Volumn 15, Issue 2, 2013, Pages 125-129

  Chahal, Gurdip S ^a   Saithna, Adnan ^a   Brewster, Mark ^a   Gilbody, Julian ^a   Lever, Suzanne ^a   Khan, Wasim S ^b   Foguet, Pedro ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Arthroplasty; Complications; Enoxaparin; Rivaroxaban; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; MORPHOLINE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

ADVERSE EFFECTS; AGED; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; HIP ARTHROPLASTY; HIP PROSTHESIS; HUMAN; KNEE ARTHROPLASTY; KNEE PROSTHESIS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PROCEDURES; PROSTHESIS-RELATED INFECTIONS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WOUND HEALING;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; ENOXAPARIN; FEMALE; HIP PROSTHESIS; HUMANS; KNEE PROSTHESIS; MALE; MIDDLE AGED; MORPHOLINES; POSTOPERATIVE CARE; PROSTHESIS-RELATED INFECTIONS; THIOPHENES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WOUND HEALING;

EID: 84877662021     PISSN: 15093492     EISSN: None     Source Type: Journal    
DOI: 10.5604/15093492.1045953     Document Type: Article

References (13)

1. Atkins RM. NICE and venous thromboembolism. J Bone Joint Surg [Br] 2010;92-B:609-10.
2. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75.
3. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9.
4. Lassen MR, Ageno W, Borris LC, et al; RECORD3 versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86.
5. Turpie AG, Lassen MR, Davidson BL, et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80.
6. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. NICE technology appraisal guidance 170.http://www.nice.org.uk/nicemedia/live/12133/43811/43811.pdfAccessed 11th March 2011.
7. Van Thiel D, Kalodiki E, Wahi R, et al. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery. Clin Appl Thromb Hemost 2009;15:389- 94.
8. Longo UG, Maffulli N, Denaro V. Rivaroxaban versus enoxaparin after total knee arthroplasty. Lancet 2009;374:681-2.
9. Raju NC, Dimmitt S, Eikelboom JW. Rivaroxaban versus enoxaparin after total knee arthroplasty. Lancet 2009;374:681.
10. Stief T. Rivaroxaban versus enoxaparin after total knee arthroplasty. Lancet 2009;374:681.
11. Gómez-Outes A, Suárez-Gea ML, Blázquez-Pérez A, Poxo-Hernández C, Vargas- Castrillón E. Rivaroxaban versus enoxaparin after total knee arthroplasty. Lancet 2009;374:682.
12. Lotke PA. Rivaroxaban for thromboprophylaxis. N Engl J Med 2008;359:2174.
13. Jensen CD, Steval A, Partington PF, Reed MR, Muller SD. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban. J Bone Joint Surg [Br] 2011;93-B:91-95